AU Patent

AU2014369850A1 — Methods and compositions for the specific inhibition of Glycolate Oxidase (HAO1) by double-stranded RNA

Assigned to Novo Nordisk AS · Expires 2016-07-14 · 10y expired

What this patent protects

This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

USPTO Abstract

This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

Drugs covered by this patent

Patent Metadata

Patent number
AU2014369850A1
Jurisdiction
AU
Classification
—
Expires
2016-07-14
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.